A Day at CPHI Americas 2025 – What to Expect

CPHI returns to Philadelphia from May 20-22, 2025 under a new name – CPHI Americas. As we aim to bring together pharma professionals for 3 days of innovation and collaboration, CPHI Americas 2025 hopes to recognise the growing influence of the Americas in the pharmaceutical and healthcare sectors. 

Bioproduction Zone and Theatre 

Discover the future of bioproduction with the all-new bioproduction zone at CPHI Americas. Featuring a range of companies dedicated to the biopharmaceutical production of biologics, biosimilars, and advanced manufacturing, this zone is your gateway to key players and innovators in bioproduction. 

As a sector, the production of biologics has seen a marked growth in interest and investment from all sectors of the pharmaceutical industry. With the rise of GLP-1 agonoists and its biosimilars already in the pipeline, and cell and gene therapies achieving more US FDA approvals than other advanced therapies to date (14+ gene therapies and 10+ cell therapies approved as of 2024), bioproduction and bioprocessing will be a major focus for all in the industry.  

Conference Tracks 

CPHI Americas once again brings together pharmaceutical experts and thought-leaders together at our conference tracks for 3 days of stimulating conversations and knowledge-sharing. This year, we are focusing on the following themes spread across two theatres – the Mainstage Theatre and the Innovation Theatre: 

Market Trends in Pharma 

This track will take a look at the biggest trends shaking up the pharmaceutical supply chain in the Americas. From the boom in GLP-1 therapies to nearshoring efforts and their effects on the wider supply chain, our speakers examine the market dynamics currently shaping pharmaceutical sponsors and vendors and beyond. 

Discover sessions such as ‘Biosecure Act: A Cure for Supply Chain Weakness or More Red Tape?’ from Claudia Lin of Pharmatech Associates, and Examining the Costs of Going Green in US Pharma with Scott Weitze of My Green Lab. 

Optimizing the US Value Chain 

As the pharmaceutical industry continues to ponder how the global supply chain will protect against current and future disruptions, this track focuses on the US Value Chain and covers topics related to supply chain resilience, APIs, and tech transfer in drug manufacturing. 

Here, we will feature speakers such as Karen Florjancic of Abbvie who will be discussing R&D CMC Outsourcing Manufacturing, and a panel on Futureproofing US Pharma and Tackling Emerging Challenges in Supply Chain Strength. 

Biotech IPOs 

Dive into our Bio-Innovation Theatre where we will host a track on R&D studies from biotechs, the recovery of IPOs for biotechs, and how a combination of increased M&A interest, evolving investor preference, and alternative capital-raising options are driving resilience and adaptability for the pharma industry. 

Learn more in our panel discussion on The Investment Heat Map: Where Capital’s Surging and Where It’s Not with speakers like Maha Radhakrishnan of Sofinnova Investments, Brian Scanlan of Edgewater Capital, and Stella Vnook of Likarda, among others. 

Bio-Innovation 

Explore the technologies and regions priming the pharmaceutical industry for dynamic innovation in the coming years. This track will highlight R&D advancements in pharma, the next wave of advanced therapeutic innovation, and how the pharma outsourcing sector can support their partners. 

Hear from Vatsala Sadasivan of Sanofi on how to empower excellence in R&D with process efficiencies, Lori Ball of Astoriom on Safeguarding R&D Samples, and many more. 

Clinical Innovation and Technology 

With the ever-changing landscape of clinical trial decentralisation and adapting trials to the future of research, this track will feature speakers such as Kenneth Getz of the Tufts Center for the Study of Drug Development and Archana Sah of AS Pharma Advisors to explore how clinical innovations are placing patients first with advancing technology. 

CP(HInt): The Main Stage Theater and Bio-Innovation Theater are right across from each other, so split your time between the two to get the most out of all our conference sessions. 

Emerging Professionals Badge 

The pharmaceutical industry can be an intimidating place, made up of big, powerful companies, heavily involved in global politics and healthcare, trying to get a foot in the door can seem a daunting prospect. 

As CPHI is one of the world’s largest facilitators for building connections in pharma, whether business to business or on a more individual level, it is well placed to open that door into the industry for emerging professionals. 

CPHI aims to embody a guiding figure for professionals in pharma just starting out and in the first 3 years of their careers. To do this, at CPHI Americas we have launched a new attendee badge, the Emerging Professionals badge, for a reduced, more accessible price. 

The badge will not only allow admittance to CPHI Americas in Philadelphia, but grant access to the content sessions, where you can learn about the latest trends and challenges in the industry, the CPHI app, where you can learn about the show and connect with other pharma professionals, access to the Match and Meet areas, where you can grow your network, and an exclusive welcome gift to help promote career progression. 

Make the most of CPHI Americas and find out from the experts what they wished they’d known at the start of their careers. 

CP(HInt): Meet and connect with professionals from every sector of the America’s pharmaceutical industry, from custom manufacturing to APIs to packaging, with your exclusive event platform dedicated to seamlessly planning your event. Download here. 

The Future of LATAM and CPHI Americas 

With the renaming of CPHI Americas to broaden the focus and encompass the whole of the American continent, this year’s event will highlight in particular the rise of the LATAM pharmaceutical market and supply chain.  

Poised for significant growth in the coming years, the LATAM pharma market is already valued at US$98 billion, with an expected growth of 10.1% and the possibility of surpassing both the North American market (3.1%) and Europe (3.9%) [1]. The region has been driven by the demand in immunity products, especially post-COVID-19, as well as plant-based solutions, improved dosage formats, and boosted awareness for disease prevention [2]. Technological innovation in the LATAM pharma market – such as nanotechnology, enhanced AI applications, and digital healthcare – are gaining momentum in an exciting part of the pharmaceutical world [2]. 

Featuring speakers from across the LATAM pharmaceutical market, including Juan de Villafranca of the AMELAF (Mexican Pharmaceutical Laboratories Association), Ricardo Castro of Elysian Bio, Sandra Sanchez-Oldenhage of Pharmadvice, and more, we will be hosting sessions and panels – including Breaking Ground Together: Unlocking Collaborative Opportunities in the LATAM Pharma Market - discussing where the pharmaceutical supply chain in LATAM is headed. We are excited to bring your attention to one of the most exciting markets emerging in recent years.  

Start-Up Market 

The Start-Up Market returns to CPHI Americas for another year of networking and connection. For companies introducing an innovative concept to the market that is scalable and demonstrates the potential for positive impact in the Americas pharma market, the Start-Up Market offers a unique opportunity to showcase innovative solutions from emerging companies, engage industry leaders and entrepreneurs in a dynamic and collaborative environment, and position emerging businesses in front of thousands of industry professionals, investors, and clients. Some of the Start-Ups slated to participate in this year’s Market include: 

The Biologics Manufacturing Centre (BMC) Inc. 

An end-to-end GMP biomanufacturing facility, BMC Inc. Supports the growth of domestic biomanufacturing production capacity, with the aim of promoting access to essential biologics at home in Canada and abroad. As an independent not-for-profit governmental organisation, The BMC strives to ensure public response to diseases are supported through key partnerships with industry and academia to advance and accelerate innovation within the life sciences sector. 

BPR Hub 

Challenges related to regulatory compliance documentation and auditing remain a thorn in the pharmaceutical industry’s side. BPR Hub offers an automated solution to various industries, including pharmaceuticals and biomanufacturing, to integrated multiple compliance standards into a single platform, automating documentation, audits, and operational tracking, giving companies time to focus on operational efficiency and innovative growth. 

ImmuNovX Biotech 

Vaccine innovation became a core focus for the pharmaceutical industry during and right after the COVID-19 pandemic. Today, vaccine technology has entered a new age as vaccine-preventable diseases become the target for many companies around the world. ImmuNovX Biotech provides an innovative platform technology to power the rapid, large-scale, and cost-effective production of live-attenuated, replication-defective antigens for a new class of vaccines against DNA-containing pathogens, promising to be a game-changer for addressing global diseases in the US and worldwide. 

At the Heart of Pharma 

Whether you’re looking for the opportunity to network with industry professionals, gain insight into the pharmaceutical supply chain, or discover solutions to existing challenges, CPHI Americas is your gateway to the heart of pharma across the Americas market. 

Register to attend CPHI Americas here. 

References 

[1] The Next Frontier – Emerging Opportunities in the LATAM Pharma Market [Accessed April 15, 2025] https://www.cphi-online.com/the-next-frontier-emerging-opportunities-in-the-page000658.html  

[2] LATAM Pharma market trends from FCE Pharma [Accessed April 16, 2025] https://www.dsm-firmenich.com/en/businesses/health-nutrition-care/news/talking-nutrition/latam-pharma-market-trends-from-fce-pharma-dsm-firmenich.html